Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.
Technical advances made in the 1980s and early 1990s resulted in monoclonal antibodies that are now approved for human therapy. Novel transgenic mouse strains provide a powerful technology platform for creating fully human monoclonal antibodies as therapeutics; ten such antibodies have entered clinical trials since 1998 and more are in preclinical testing. Improved transgenic mouse strains provide a powerful technology platform for creating human therapeutics in the future.
Kellermann
Sirid Aimée
SA
Abgenix, Inc., 6701 Kaiser Drive, Fremont, CA 94555, USA.
Green
Larry L
LL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology / Q000627:therapeutic use*; D005803:Genes, Immunoglobulin; D006801:Humans; D007128:Immunoglobulin Fragments / Q000096:biosynthesis / Q000276:immunology / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments